FIELD: medicine.
SUBSTANCE: disclosed is a combination immediate/delayed release delivery system for compounds which have short half-life, such as antidiabetic remogliflozin etabonate, which provides a dosage form that has two distinct phases of release. Solid phase for immediate release includes remogliflozin etabonate and immediate release material. Solid phase of delayed release comprises remogliflozin etabonate and sustained release material. Solid phase of delayed release has shape of discrete single particles or granules and solid phase for immediate release is a matrix, which consists of separate particles of solid phase of delayed release enclosed in said matrix or dispersed therein. What is also presented is a method for producing a pharmaceutical composition.
EFFECT: invention provides a procedure for administering remogliflozina etabonate once a day.
9 cl, 4 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF OMEGA-3 FATTY ACID AND SGLT-2 INHIBITOR FOR TREATING LIVER DISEASES | 2015 |
|
RU2695652C2 |
| COMPOSITIONS OF METFORMIN WITH REDUCED WEIGHT | 2010 |
|
RU2564901C2 |
| PHARMACEUTICAL COMPOSITION BASED ON AN ACTIVE SUBSTANCE, AN INHIBITOR OF DIPEPTIDYL PEPTIDASE-4, FOR PREVENTING THE DEVELOPMENT AND TREATMENT OF TYPE 2 DIABETES MELLITUS | 2020 |
|
RU2727898C1 |
| ANTI-DIABETIC PREPARATION AND METHOD FOR TREATMENT OF DIABETES MELLITUS | 2000 |
|
RU2276604C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DIACEREIN | 2009 |
|
RU2542461C2 |
| COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF EXENATIDE | 2009 |
|
RU2566063C2 |
| COMPOSITIONS AND METHODS FOR INCREASING ENERGY METABOLISM | 2013 |
|
RU2655794C2 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| METHOD OF TREATING HYPERGLYCAEMIA | 2017 |
|
RU2739255C2 |
| PHARMACEUTICAL ANTIDIABETIC COMPOSITION BASED ON (+)-CIS-3-(1H-BENZIMIDAZOL-2-YL)-1,2,2-TRIMETHYLCYCLOPENTANE CARBOXYLIC ACID | 2016 |
|
RU2624872C1 |
